Cost-effectiveness of edaravone dexborneol versus edaravone for the treatment of acute ischemic stroke in China: Based on the TASTE study

Background and purpose: The TASTE trial indicated that patients with acute ischemic stroke (AIS) using edaravone dexborneol have a significantly higher proportion of 90-day good functional outcomes (mRS 0–1) than those using edaravone. This study compared the cost-effectiveness of the aforementioned...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Fenghao, He, Zixuan, Wang, Lin, Su, Hang, Han, Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622952/
https://www.ncbi.nlm.nih.gov/pubmed/36330098
http://dx.doi.org/10.3389/fphar.2022.938239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622952/
https://www.ncbi.nlm.nih.gov/pubmed/36330098
http://dx.doi.org/10.3389/fphar.2022.938239

Ejemplares similares